UNASSIGNED: This was a single-center, randomized, double-blind, placebo-controlled trial. Patients who developed grade 1 HFS/HFSR after systemic anticancer treatments were enrolled, and randomly assigned to receive either ATPC or placebo cream (PC) and followed up at 3-week intervals for up to nine weeks. Primary endpoint was the development of grade ≥ 2 HFS/HFSR.
UNASSIGNED: Between April 2019 and July 2022, 60 patients (31 in the ATPC and 29 in the PC group) completed the study. The incidence of grade ≥ 2 HFS/HFSR was significantly lower in the ATPC than in the PC group (25.8% vs. 51.7%, p=0.039). The ATPC showed trends towards a better QoL score, assessed by a HFSR and QoL questionnaire at 9 weeks (26.0 vs. 29.9, p=0.574), and a lower frequency of discontinuation, interruption, or dose reduction of anticancer drugs (51.6% vs. 58.6%, p=0.586) than the PC group over 9 weeks, though without statistical significance.
UNASSIGNED: Our results showed that ATPC significantly decreased the development of grade ≥ 2 HFS/HFSR in patients already with HFS/HFSR. Therefore, ATPC may be an effective treatment for HFS/HFSR associated with anticancer drugs.
■这是一个单中心,随机化,双盲,安慰剂对照试验。纳入全身抗癌治疗后出现1级HFS/HFSR的患者,并随机分配接受ATPC或安慰剂乳膏(PC),并以3周的间隔进行随访,为期9周。主要终点是≥2级HFS/HFSR的发展。
■在2019年4月至2022年7月之间,有60名患者(ATPC组31名,PC组29名)完成了研究。ATPC组≥2级HFS/HFSR的发生率显着低于PC组(25.8%vs.51.7%,p=0.039)。ATPC显示出更好的QoL评分趋势,通过9周时的HFSR和QoL问卷评估(26.0vs.29.9,p=0.574),中断的频率较低,中断,或抗癌药物的剂量减少(51.6%vs.58.6%,p=0.586)比PC组超过9周,但没有统计学意义。
■我们的结果表明,在已经患有HFS/HFSR的患者中,ATPC显着降低了≥2级HFS/HFSR的发展。因此,ATPC可能是与抗癌药物相关的HFS/HFSR的有效治疗方法。